Helen M. Thackray - 22 Sep 2021 Form 4 Insider Report for ImmunoGen, Inc.

Role
Director
Signature
/s/ Renee Lentini, attorney in fact
Issuer symbol
N/A
Transactions as of
22 Sep 2021
Net transactions value
+$262,680
Form type
4
Filing time
23 Sep 2021, 16:35:40 UTC
Next filing
16 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Deferred Share Unit Award $0 +30,000 $0.000000 30,000 22 Sep 2021 Common Stock 30,000 $0.000000 Direct F1, F2, F3
transaction IMGN Stock Option (right to buy) Award $262,680 +44,000 $5.97 44,000 22 Sep 2021 Common Stock 44,000 $5.97 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
F2 The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
F3 The deferred share units vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date.
F4 The stock options vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date.